Biogen (NASDAQ:BIIB) Issues Earnings Results

Biogen (NASDAQ:BIIB) posted its earnings results on Wednesday. The biotechnology company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63, FiscalAI reports. The firm had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.63 billion. During the same quarter in the prior year, the firm posted $4.81 earnings per share. Biogen’s quarterly revenue was up 10.6% on a year-over-year basis.

Here are the key takeaways from Biogen’s conference call:

• Q3 revenue grew 11% year over year to $2.8 billion, driven by the growth portfolio and the first full quarter of SYFOVRE and EMPAVELI following the Apellis acquisition. Biogen raised the low end of its 2026 non-GAAP EPS outlook to $12.20–$13.00.
• The Apellis integration is progressing faster than expected, with the transaction now roughly operating-income neutral and at least $250 million in run-rate synergies targeted by the end of 2027. Biogen also expects the deal to be accretive to non-GAAP EPS in 2027.
• Biogen reported strong momentum across key growth products, including high-dose SPINRAZA, LEQEMBI, SKYCLARYS, SYFOVRE and EMPAVELI. The company said its growth portfolio represented approximately 63% of core pharmaceutical revenue and expects to return to overall top-line growth in 2026.
• The company highlighted a series of potentially important clinical catalysts, beginning with phase III SLE data for litifilimab in December and followed by readouts in cutaneous lupus, AMR and Dravet syndrome. Biogen also reported five INDs in 2026 and plans to build an early-stage pipeline of at least 20 programs over the next several years.
• Several reported Q3 sales benefited from temporary factors, including SPINRAZA conversion doses and inventory builds for SKYCLARYS and SYFOVRE, which are expected to reverse in Q4; contract manufacturing revenue is also expected to decline. VUMERITY revenue fell 11% year over year due to tighter Part D formulary management, while the upcoming pipeline readouts remain subject to clinical and regulatory risk.

Biogen Stock Performance

Shares of BIIB stock traded down $2.13 during trading hours on Wednesday, reaching $250.59. 537,599 shares of the company’s stock were exchanged, compared to its average volume of 1,206,587. Biogen has a fifty-two week low of $138.00 and a fifty-two week high of $258.78. The stock’s 50 day moving average is $225.10 and its 200-day moving average is $200.10.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BIIB. Seaport Research Partners upgraded Biogen to an “outperform” rating in a report on Monday, October 12th. Wells Fargo & Company upped their target price on Biogen from $250.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, October 20th. UBS Group boosted their price objective on Biogen from $240.00 to $270.00 and gave the company a “buy” rating in a report on Friday, October 9th. Bank of America upped their target price on shares of Biogen from $219.00 to $244.00 and gave the stock a “neutral” rating in a research note on Thursday, October 22nd. Finally, Wedbush upped their target price on Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $241.89.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported adjusted earnings of $2.62 per share, exceeding the Zacks consensus estimate of $2.06 and the broader consensus cited by MarketBeat of $1.99. Revenue reached $2.804 billion, above expectations of roughly $2.63 billion and up 11% year over year. Biogen Inc. Tops Q3 Earnings and Revenue Estimates
• Positive Sentiment: Growth Portfolio revenue rose 49% to $1.26 billion, benefiting from the first full quarter of contributions from acquired Apellis products. Total product revenue increased 13%, while rare-disease revenue grew 27% to $676 million, supporting the diversification strategy beyond multiple sclerosis treatments. Biogen Q3 Revenue Rises 11% as GAAP Loss Widens
• Positive Sentiment: Management raised the lower end of its 2026 reported non-GAAP diluted EPS outlook, now guiding to $12.20–$13.00. Piper Sandler also maintained its Buy rating, reinforcing bullish sentiment around Biogen’s growth products and acquisitions. Piper Sandler Maintains Buy Rating
• Neutral Sentiment: Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, versus year-ago GAAP earnings of $466.5 million, primarily reflecting $284 million of acquired in-process research and development, upfront and milestone expenses tied largely to the RayThera acquisition. These are significant near-term charges but may support future growth.
• Negative Sentiment: GAAP earnings declined sharply from $3.17 to a loss of $0.14 per share, and the stock’s strong recent run has raised concerns that much of the expected improvement is already reflected in its valuation. Biogen also ended the quarter with approximately $7.7 billion of debt, a consideration as acquisition spending continues.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.